# Commission Decision of 23 February 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 293) (Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Portuguese, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2005/171/EC), Annex I

Extent: E+W+S+N.I.

Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following Parties have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following products:
Source: www.unep.org/ozone/dec12-2-3.pdf
ProductCountry
Salbutamol
Terbutaline
Fenoterol
Orciprenaline
Reproterol
Carbuterol
Hexoprenaline
Pirbuterol
Clenbuterol
Bitolterol
Procaterol
Beclomethasone
Dexamethasone
Fluinisolide
Fluiticasone
Budesonide
Triamcinolone
Ipratropium bromide
Oxitropium Bromide
Austria
X
X
X
X
X
X
X
X
X
X
X
Belgium
X
X
X
X
X
X
X
X
X
X
X
Czech Republic
X
X
X
X
X
X
X
X
X
X
X
Denmark
X
X
X
X
X
X
X
X
X
X
X
Finland
X
France
X
Germany
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Greece
X
X
X
X
X
X
X
X
X
X
X
Ireland
X
Luxembourg
X
Portugal
X
X
X
X
X
X
X
X
X
X
X
The Netherlands
X
X
X
X
X
X
X
X
X
X
X
Norway
X
X
X
X
X
X
X
X
X
X
X
Sweden
X
UK
X

---
Source: https://www.legislation.gov.uk/eudn/2005/171/annex/I (the official version)
Page: https://openlegislation.uk/eu-decision-2005-171/annex-I
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.